



May 10, 2019

Dr. Kevin Smith
President & CEO, University Health Network
kevin.smith@uhn.ca

Dr. Brian D. Hodges
EVP and Chief Medical Officer
brian.hodges@uhn.ca

Dear Drs. Smith and Hodges

Our research, published in PLoS One in late February as you know, revealed significant adverse effects for some UHN patients. It is our ethical obligation as physicians and researchers to inform each patient so affected. We trust that you will ensure we have the help and accommodation of the Thalassemia Clinic in contacting all patients with whom we are obligated to meet.

As there is some urgency to informing patients, we look forward to your confirmation of assistance in the next few days. We will contact your office if you have not replied by next Wednesday May 15, 2019. If you have any questions or would like to talk with us, please let us know. We are copying this to the Head of Oncology and Hematology, Dr. Amit Oza, to help ensure we can meet with the affected patients in a timely manner.

Yours sincerely,

A handwritten signature in black ink that reads "Brenda L. Gallie".

Brenda L. Gallie, MD, FRCSC, CM, OOnt
Head, Retinoblastoma Programs,
Hospital for Sick Children and Alberta Children's Hospital
Associate Scientist, TECHNA Institute, UHN
Professor, Ophthalmology, Medical Biophysics,
Molecular Genetics, University of Toronto
555 University Ave, Toronto M5G 1X8
brenda@gallie.ca

A handwritten signature in black ink that reads "Nancy Olivieri".

Nancy F. Olivieri, MD, MA, FRCPC
Professor, Pediatrics, Medicine and Public Health Sciences,
University of Toronto, Canada;
Senior Scientist, Toronto General Hospital, UHN
200 Elizabeth Street, EN 13-222,
Toronto, Ontario Canada M5G 2C4
nancy@hemoglobal.org

cc: Dr. Michael Baker, Michael.Baker@uhn.ca
Dr. Amit Oza, Amit.Oza@uhn.ca.